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INTRODUCTION 
 
Infections that occur in the wound created by an invasive surgical 
procedure are generally referred to as surgical site infections (SSIs). SSIs are 
one of the most important causes of healthcare-associated infections (HCAIs). A 
prevalence survey undertaken in 2006 suggested that approximately 8% of 
patients in hospital in the UK have an HCAI. SSIs accounted for 14% of these 
infections and nearly 5% of patients who had undergone a surgical procedure 
were found to have developed an SSI.
(1)
  
 
However, prevalence studies tend to underestimate SSI because many of 
these infections occur after the patient has been discharged from hospital. 
SSIs are associated with considerable morbidity and it has been reported that 
over one-third of postoperative deaths are related, at least in part, to SSI.
(2)
  
  
In patients undergoing laparotomy with contaminated and dirty wounds 
the infection rate is 20% to 30% and 30% to 40% respectively.
(3),(4) 
 
SSIs leads to severe morbidity in the operated patient in the form of costs 
of treatment and prolonged hospital stay and the need for redo surgery in some 
cases. Most infection occur from the skin and superficial microbes and various 
methods can be used to tackle this condition by using this matter of fact. 
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Several preventive steps are followed and recommended by most of the 
surgical research teams and the use of local antibiotic over the wound site as an 
attempt to prevent the surgical site infection is one of them. A cost effective and 
adequately sufficient method is being studied to prevent surgical site infection 
through this method. 
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AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
An prospective case control study 
 
1. To analyse the effects of local antibiotic (Amikacin) therapy at the 
surgical site along with systemic antibiotic therapy in an attempt to 
prevent surgical site infections in contaminated and dirty surgical wounds 
as compared to that of systemic antibiotics alone. 
 
2. Grading the SSIs in both the groups and study the effects of local 
antibiotic in reducing the incidence/severity of SSIs  at the end of first 
and second week of the post operative period 
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REVIEW OF LITERATURE 
 
Defining surgical site infection 
 
 Postoperative wound infections, also known as surgical site infections 
(SSIs), complicates many surgical patients. As defined by the Centers for 
Disease Control and Prevention (CDC), these infections typically occur within 
30 days of an operation at the site or part of the body where the surgery took 
place, or within a year if an implant is left in place and the infection is thought 
to be secondary to surgery.
(5–7)
   SSI is now the most common and most costly 
hospital acquired infection.
(31-33)
 
 
Since skin is normally colonised by a range of microorganisms that could 
cause infection, defining an SSI requires evidence of clinical signs and 
symptoms of infection rather than microbiological evidence alone. SSIs 
frequently only affect the superficial tissues, but some more serious infections 
affect the deeper tissues or other parts of the body manipulated during the 
procedure. 
 
The majority of SSIs occurs most often between the 5th and 10th 
postoperative days. However, where a prosthetic implant is used, SSIs affecting 
the deeper tissues may occur several months after the operation. 
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Although the outcome measure for SSI used by many studies is based on 
tandard definitions such as those described by the Centers for Disease Control 
and Prevention (CDC)
(8)
 or the Surgical Site Infection Surveillance Service,
(9)
 
other valid measures based on clinical signs and symptoms have been described 
such as the Southampton
(10)
 and ASEPSIS
(11)
 methods. 
 
Figure 1 – different types of surgical site infections, three levels (87) 
 
The CDC definition
(12)
 describes three levels of SSI: 
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• superficial incisional, affecting the skin and subcutaneous tissue. These 
infections may be indicated by localised (Celsian) signs such as redness, pain, 
heat or swelling at the site of the insicion or by the drainage of pus. 
• deep incisional, affecting the fascial and muscle layers. These infections may 
be indicated by the presence of pus or an abcess, fever with tenderness of the 
wound, or a separation of the edges of the incision exposing the deeper tissues. 
 
• organ or space infection, which involves any part of the anatomy other than 
the incision that is opened or manipulated during the surgical procedure, for 
example joint or peritoneum. 
 
These infections may be indicated by the drainage of pus or the formation 
of an abscess detected by histopathological or radiological examination or 
during re-operation.  
 
In addition, there may also be microbiological evidence of wound 
infection from cultures obtained aseptically from wound fluid or tissue. 
However, since skin sites are normally colonized by a variety of organisms, 
positive wound cultures in the absence of clinical signs are rarely indicative of 
SSI. Some studies report infections that affect any part of the incision, whereas 
other studies focus only on those that affect the deeper tissues as these may be 
considered to be more important and their definition less subjective. Variation 
introduced by the definition of SSIs and the methods used to detect them need 
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to be taken account when combining or comparing evidence from different 
studies. This variation has been an important limiting factor in reviewing 
evidence for  this guideline. 
 
Surveillance for surgical site infection 
Surveillance of SSI provides data that can both inform and influence 
practice to minimise the risk of SSI, as well as communicate more clearly the 
risks of infection to patients.
(13)
 Surveillance was first recognised as an 
important tool in reducing rates of infection in the 1980s.
(14)
  The Study on the 
Efficacy of Nosocomial Infection Control (SENIC) showed that surveillance 
and infection control programmes that included the collection, analysis and 
feedback of data on infection rates to surgeons were associated with significant 
reductions in rates of SSI.
(15)  
 
Since then, many  national surveillance systems have been established 
and have reported reductions in rates of SSI in association with surveillance, 
feedback of data to clinicians and benchmarking of rates of SSI.
(9–12)
 Consumer 
demand for information about the performance of healthcare providers has also 
led to compulsory public reporting of data on HCAIs, including SSIs.  
 
National surveillance systems, such as the Surgical Site Infection 
Surveillance System in England and similar schemes in Wales and Northern 
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Ireland, provide standardised surveillance methods that enable hospitals to 
benchmark their rates of SSI.  
 
Such benchmarking can be a powerful driver for change but requires 
participating hospitals to use uniform methods of finding and defining cases of 
SSI that are likely to reliably identify a large proportion of the infections, and a 
reliable approach to analysing rates of SSI that takes account of variation in risk  
associated with different procedures and risk factors in the patients undergoing 
surgery. Most national surveillance systems target surveillance towards defined 
groups of patients undergoing similar operative procedures, following each case 
up to identify those that develop an SSI, although the sensitivity of case-finding 
will be influenced by the methods employed.
(16)
  
 
This enables rates of SSI to be calculated using the number of procedures 
as the denominator. Feedback of rates to individual surgical teams and 
comparisons with the benchmark rate are essential components of effective 
surveillance.
(15)
 The risk index developed by the CDC in the USA, which takes 
account of the underlying illness of the patient, the duration of the operation and 
the wound classification of the procedure, is commonly used to adjust rates of 
SSI and improve the validity of comparisons where case-mix may vary over 
time or between centers.
(17)
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 However, comparisons between different surveillance systems is 
complicated because of variation in both the methods of surveillance and the 
application and interpretation of case definitions.
(18) 
Since some SSIs may take 
many days to develop, evidence of infection may not become apparent until 
after the patient has been discharged from hospital.  
 
Surveillance focused on detecting SSI during the inpatient stay is thus 
likely to underestimate the true rate of SSI, a problem that is exacerbated by the 
increasing trend towards shorter lengths of postoperative hospital stay and 
day surgery.
(19)
 Therefore, systems that enable cases of SSI to be identified after 
discharge from hospital enhance the value of surveillance. However, there are a 
number of practical difficulties in reliably identifying SSI in community 
settings and methods that systematically and accurately identify SSI are 
required if valid comparisons of rates are to be made.
(20)  
 
 It is important to note that no such centralized system to report SSIs 
exists in our nation as of now, and it should be considered in the future to create 
a system to detect analyse and audit this serious post operative nosocomial 
complication of surgical patients 
Risk factors 
The risk of SSI is increased by factors that: 
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• increase the risk of endogenous contamination (for example, procedures 
that involve parts of the body with a high concentration of normal flora such as 
the bowel) 
• increase the risk of exogenous contamination (for example, prolonged  
operations that increase the length of time that tissues are exposed) 
• diminish the efficacy of the general immune response (for example, 
diabetes, malnutrition, or immunosuppressive therapy with radiotherapy, 
chemotherapy or steroids) or local immune response (for example, foreign 
bodies, damaged tissue or formation of a haematoma). 
 
Randomised controlled trials, which require the assessment of 
comparability between groups, have not been undertaken for risk factors.  
 
While data on risk factors for SSI are available from observational studies 
using regression analyses, factors that are significant in one type of surgery may 
not be generalisable to other surgical procedures. 
 
Age: 
Five studies were identified.
(9,21–24)
One prospective observational study 
using logistic regression to analyse data collected from 142 medical centres 
identified age as an independent risk factor for SSI.
(21)
. Trained nurses gathered 
data on inherent and operative risk factors for SSI in patients undergoing 
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general and vascular surgery. Of 163 624 patients who were included in the 
study, 7035 developed SSI
(17)
within 30 days of surgery.  
 
Patients aged over 40 had a statistically significantly increased risk of 
developing SSI compared with those under 40 years (OR 1.24, 95% CI 1.07 to 
1.44). Another prospective observational study examined SSI in patients 
undergoing total hip replacement, hemiarthroplasty or revision procedures as 
part of SSI surveillance in England.10 [EL = 2+] Trained personnel collected 
clinical and operative data throughout the duration of the hospital stay. 
Detected cases of SSI were thus classified as occurring in the immediate 
postoperative period. 
 
Age over 75 was found to be a significant risk factor (compared with a 
baseline of age under 65) when all types of hip replacement were considered  
together (for age 75–79 years OR 1.56, 95% CI 1.16 to 2.10, for age ≥ 80 years 
OR 1.66, 95% CI 1.24 to 2.21). 
 
A retrospective observational study conducted in the USA included 
patients who underwent general surgery with antibiotic prophylaxis at a 
community hospital.
(22) . 
Demographic and clinical information was extracted 
from the database including readmission up to 28 days post-surgery.  
Regression techniques were used to identify independent risk factors for SSI 
detected early (between 2 and 7 days postoperatively), necessitating 
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readmission or causing death. Age was found to be a statistically significant risk 
factor for early SSI incidence (SSI incidence for each decade increase in age 
OR 1.22, P < 0.01). 
 
One large prospective study (n = 23 649 wounds) including children and 
adults undergoing procedures on mostly clean wounds stratified results by age 
group
.(23)
 Observations of SSI were made for 28 days postoperatively and a 
broad trend of increasing SSI incidence with increasing age was reported. 
 
A prospective cohort study of adult surgical patients (n = 144 485) from 
11 hospitals reported an SSI incidence rate of 1.2%.24 [EL = 2+] A direct linear 
trend of increasing risk of deep or organ space SSI from age 17 until age 65 
(1.1% for each year of age, P < 0.002) was reported. However, for patients aged 
over 65 the risk of SSI decreased by 1.2% for each extra year of life (P = 0.008)  
 
Underlying illness 
The American Society of Anesthesiologists’ (ASA) classification of 
physical status score is used to assess a patient’s preoperative physical condition 
and provides a simple measure of the severity of the underlying illness. Four 
studies were identified that found ASA score to be an indicator of 
SSI development.
(9,17,21,24) 
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A prospective cohort study of adult surgical patients (n = 144 485) from 
11 hospitals reported an SSI incidence rate of 1.2%.24 [EL = 2+] A statistically 
significantly higher SSI incidence for those with an ASA score of 3 or greater 
compared with those with an ASA score of 1 or 2 (OR 3.0, 95% CI 2.6 to 3.2) 
was reported. 
 
This effect was also demonstrated in a prospective observational study 
examining SSI in patients undergoing total hip replacement, hemiarthroplasty or 
revision procedures.
(9)
 . Cases of SSI occurring in the immediate postoperative 
period were included.  
 
Overall, the SSI incidence rate was 3.07% (n = 24 808 procedures, cases 
of SSI = 761). Multivariate analysis showed ASA score of 3 or greater to be an 
independent risk factor for SSI (OR 1.55, 95% CI 1.29 to 1.88). 
 
A prospective observational study using logistic regression to analyse 
data collected from patients undergoing general or vascular surgery in 142 
medical centres also identified ASA score as an independent risk factor for 
SSI.21 [EL = 2+] The SSI incidence rate was 4.3%. Compared with an ASA 
score of 1, a score of 3 and a score of 4 or 5 were found to be statistically 
significantly associated with SSI (OR 1.97, 95% CI 1.53 to 2.54 and OR 1.77, 
95% CI 1.34 to 2.32, respectively). 
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In one retrospective observational study, analysis of data from the 
National Nosocomial Infections Surveillance System (n = 84 691 operations) 
found an overall SSI incidence of 2.8%.
(17)
 .The majority of patients (94%) were 
undergoing clean or clean-contaminated surgery. The strength of association 
between ASA score and SSI development risk was estimated (Goodman–
Kruskal Gstatistic = 0.34, standard error (SE) = 0.01) and stratification of 
results by ASA score demonstrated that the rate of SSI increased by a factor of 
4.7 as ASA score ranged between 1 (1.5 SSIs per 100 operations) to 5 (7.1 SSIs 
per 100 operations). 
 
In addition, there are some specific underlying diseases or conditions that 
are independently associated with an increased risk of SSI.
 
Surgical site 
infection.A number of studies in cardiac, spinal, vascular and general surgery 
and have shown that diabetes is strongly associated with an increased risk of 
SSI.
(21,23,25–29) 
 Studies report a two- to three-fold increase in risk of developing 
an SSI in patients with diabetes. This may be related to altered cellular immune 
function. 
 
A prospective cohort study (with a parallel case–control analysis) of 1044 
cardiothoracic surgery patients demonstrated evidence that the rate of SSI is 
independently associated with postoperative hyperglycaemia (OR 2.02, 95% CI 
1.21 to 3.37) and that the risk of SSI correlated with the degree of 
hyperglycaemia during the postoperative period (for patients with postoperative 
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glucose levels of 200–249 mg/dl, 250–299 mg/dl and ≥ 300 mg/dl, SSI ORs 
were 2.54, 2.97 and 3.32, respectively).
(27)
  
 
One large prospective study of procedures on mostly clean wounds in 
children and adults reported that malnourishment increased the incidence of SSI 
from 1.8% to 16.6% (univariate analysis).
(23)
 Two studies were identified that 
found low serum albumin to be an indicator of SSI development.
(21,22) 
In a large prospective cohort study of general and vascular surgery patients (n = 
163 624 patients), multivariate analysis demonstrated that those with a low 
preoperative serum albumin (≤ 3.5 g/dl) were more likely to develop SSI (OR 
1.13, 95% CI 1.04 to 1.22), compared with those with normal serum albumin 
levels.
(21)
 
 
The results of a retrospective observational study of patients undergoing 
general surgery with antibiotic prophylaxis (n = 9016) further suggested that 
low serum albumin was associated with the development of SSI within the first 
2–7 days postoperatively (OR 2.27, P < 0.01, per gram percent decrease).(22)  
One study was identified that found treatments associated with anti-cancer 
therapy to be indicators of SSI development.
(21)
 
 
 The prospective cohort of general and vascular surgery patients also 
found that radiotherapy within 90 days prior to surgery (OR 1.37, 95% CI 1.08 
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to 1.74) and use of steroids (OR 1.39, 95% CI 1.18 to 1.63) independently 
predicted development of SSI.
(21)
 
 
Obesity 
Adipose tissue is poorly vascularised and the consequent effect on 
oxygenation of the tissues and functioning of the immune response is thought to 
increase the risk of SSI. In addition, operations on patients who are obese can be 
more complex and prolonged.
(30)
 The effect of obesity on the risk of SSI has 
been investigated in cardiac and spinal surgery and in caesarean section. Studies 
report ORs of between 2 and 7 for SSI in patients with a body mass index of 35 
kg/m2 or more.
(23,25–31) 
 
Smoking 
The wound healing process may be affected by the vasoconstrictive 
effects and reduced oxygencarrying capacity of blood associated with smoking 
cigarettes. Four studies were identified that investigated the association of 
smoking with SSI development.
(21,26,29,32) 
 
One prospective observational study, using logistic regression to analyse 
data collected from patients (n = 163 624) undergoing general and vascular 
surgery in 142 medical centres, identified smoking as an independent risk factor 
for SSI.21 [EL = 2+] Smokers had a statistically significantly greater risk of 
developing SSI compared with non-smokers (OR 1.23, 95% CI 1.04 to 1.22). 
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A case–control study of adults undergoing cardiac surgery (n = 117) 
examined risk factors for SSI.29 [EL = 2+] Statistically significantly more 
patients who developed an SSI smoked compared with uninfected controls 
(28.2% versus 14.1%) and, following logistic regression analysis, 
smoking remained an independent risk factor for SSI (OR 3.27, 95% CI 1.04 to 
10.20) 
 
A prospective observational study investigated SSI in patients undergoing 
breast reduction surgery.32 [EL = 2+] Participants (n = 87) were instructed to  
stop smoking at least 4 weeks prior to surgery. Twenty-four patients developed 
SSI, which occurred 8 days postoperatively on average. Statistically 
significantly more smokers developed SSI than non-smokers (37.2% versus 
18.2%, P < 0.05). Sixteen of 43 smokers developed SSI. Those who smoked 
more cigarettes were more 
(19) 
likely to develop SSI (estimated cigarettes 
smoked mean 146 000 range 29 200–228 125 versus mean 10 950 range 9125–
54 750, P < 0.001) and those who had smoked for a longer time also 
experienced statistically significantly more infections (mean pack years 20, 
range 4–31 versus mean pack years 2, range 1–8, P < 0.001) 
 
A retrospective observational study of cardiac surgery (n = 3008) 
investigating risk factors for SSI, using logistic regression techniques, found 
that smokers developed statistically significantly more sternal SSIs (OR 1.39, 
95% CI 1.05 to 1.86) and deep sternal SSIs (OR 2.41, 95% CI 1.42 to 4.10) than 
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non-smokers and that peripheral vascular disease was also an independent risk 
factor for the development of deep SSI (OR 2.11, 95% CI 1.09 to 4.09).
(26)
 
 
A further prospective study of cardiac surgery patients reported 199 SSIs 
occurring within 2345 included participants.
(28)
 . Multivariate analysis also 
demonstrated that generalized peripheral vascular disease statistically 
significantly increased the risk of SSI (OR 1.64, 95% CI 1.16 to 2.33). 
 
Wound classification 
The significance of the microbial flora normally colonising the operative 
site in the subsequent risk of SSI has been recognised for many decades. The 
wound classification developed by the  
 
National Academy of Sciences in the 1960s distinguishes four levels of 
risk, from clean, where the procedure involves a sterile body site, to dirty, 
where the procedure involves a heavily contaminated site. 
Three studies were identified that examined the association of wound 
classification with SSI incidence.
(16,21,24) 
In a retrospective analysis of a large 
infection surveillance data set, the SSI incidence rate per 100 operations was 
2.1, 3.3, 6.4, 7.1 for clean, clean-contaminated, contaminated and dirty wound 
classes, respectively.
(17)  
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Figure 2 – per operative image during laprotomy done for pyoperitoneum, 
showing pus from the abdominal cavity 
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Another study of general and vascular procedures reported that wound 
class was an independent predictor of SSI (clean surgery SSI OR 1 , SSI ORs 
for clean-contaminated, contaminated and dirty wound classes were 1.04, 1.7 
and 1.5, respectively, P < 0.0001),
(21)
while a third prospective study found that 
SSI was statistically significantly increased in contaminated and 
dirty wounds (wound class > 2 OR 2.3, 95% CI 2.0 to 2.7).
(24) 
 
Site and complexity of procedure 
For many types of surgery there is evidence that the risk of SSI is 
affected by the specific site of the operation.Complexity of the procedure is also 
indicated as an SSI risk factor.  
 
One study of general and vascular surgery estimated that there was a two- 
to three-fold increased risk of SSI with increasing surgical complexity measured 
as work relative value units.
(21)
 However, complex surgery is more often 
distinguished by prolonged duration of the procedure. In studies of cardiac and 
hip replacement surgery,
(9)
 there was a 1.5- to 1.75-fold increased risk of SSI 
associated with longer duration of surgery. 
 
While some of these patient characteristics, such as obesity, 
hyperglycaemia, malnutrition and smoking, may be modified prior to surgery, 
others, such as the complexity of the procedure and the underlying illness in the 
patient, cannot.Mechanisms of accounting for variation in intrinsic 
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characteristics of patients or procedures that influence the risk of SSI are 
important for surveillance  systems in order to enable valid comparisons of rates 
among surgeons, among hospitals, or across time. Early surveillance systems
(23)
 
used the basic wound classification to adjust for risk of SSI but analyses of 
large data sets on a range of operative procedures identified a few key risk 
factors that were associated with an increased risk of SSI and that when used in 
combination  provided a better indicator of risk of SSI than the wound 
classification.
(21,25)
  
 
This National Nosocomial Infection Surveillance (NNIS) system risk 
index is based on the presence of the following risk factors: 
1. a patient with an ASA preoperative assessment score of 3, 4 or 5 (a 
simple measure of the 
severity of the patient’s underlying illness) 
2. an operation classified as contaminated or dirty-infected 
3. an operation lasting over T hours, where T depends on the operative 
procedure being performed.
(2,16)
 The T time is the 75th percentile of the 
distribution of operation time for a particular category of procedures rounded to 
the nearest hour.
(17) 
. While this NNIS risk index does not measure all the factors 
that contribute to the risk of developing an SSI, it does provide a practical way 
of adjusting rates for the major patient and operative risk factors and it is used 
to stratify rates of SSI by most national surveillance systems.  
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Other more complex risk stratification systems to predict the risk of SSI have 
also been developed.
(21,26) 
 
Evidence statements on risk factors 
Age 
The age of the patient is a significant independent predictor of the risk of SSI 
development generally and for early SSI development.  
Moreover, in adults a direct linear trend of increasing risk of SSI until age 65 
has been demonstrated.  
For those aged over 65, an inverse linear trend of SSI risk was found, although 
this finding may be subject to selection bias (i.e. only those who are fit enough 
undergo surgery).  
 
Underlying illness 
Those patients with an ASA score of 3 or more have a severe systemic disease 
and have been found to have a significantly higher risk of SSI.  
Studies have repeatedly shown that diabetes is strongly associated with an 
increased risk of SSI.  
Malnutrition has been implicated as a risk factor for SSI 
There is evidence from a prospective and a retrospective study that the risk of 
SSI is increased in patients with a low serum albumin. 
Radiotherapy and steroid use have both been linked to an increased risk of SSI.  
Obesity 
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Studies have repeatedly shown that obesity is strongly associated with an 
increased risk of SSI. 
 
Smoking 
Smoking, duration of smoking and number of cigarettes smoked are associated 
with an increased risk of SSI.  
Peripheral vascular disease has been demonstrated to increase SSI risk in a 
prospective and a retrospective study. 
 
Wound classification 
There is consistent evidence that the risk of infection increases with level of 
wound contamination. 
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Strategies to prevent surgical site infection: 
Now that we have analysed the factors which are risk factors for 
developing a surgical site infection let us go the various steps and 
recommendations used to prevent this complication in surgical patients. 
 
Recommendations are categorized as either (1) basic practices that should 
be adopted by all acute care hospitals or (2) special approaches that can be 
considered for use in locations and/or populations within hospitals when HAIs 
are not controlled by use of basic practices.  
 
Basic practices include recommendations where the potential to impact 
HAI risk clearly outweighs the potential for undesirable effects. Special 
approaches include recommendations where the intervention is 
likely to reduce HAI risk but where there is concern about the risks for 
undesirable outcomes resulting from the intervention, where the quality of 
evidence is low, or where evidence supports the impact of the intervention in 
select settings (eg, during outbreaks) or for select patient populations. 
 
Hospitals can prioritize their efforts by initially focusing on 
implementation of the prevention approaches listed as basic practices. If HAI 
surveillance or other risk assessments suggest that there are ongoing . 
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opportunities for improvement, hospitals should then consider adopting some or 
all of the prevention approaches listed as special approaches. These can 
be implemented in specific locations or patient populations or can be 
implemented hospital-wide, depending on outcome data, risk assessment, and/or 
local requirements. 
. 
I. Basic practices for preventing SSI: recommended for all 
acute care hospitals 
1. Administer antimicrobial prophylaxis according to evidence- based 
standards and guidelines. 
(34-36)
 
 
a. Begin administration within 1 hour before incision to maximize 
tissue concentration.
(37,38)
  Administering agent closer than 1 hour is 
effective, and some studies show superior efficacy for administration 
between 0 and 30 minutes prior to incision compared with administration 
between 30 and 60 minutes.
(39,40) 
. Two hours are allowed for the 
administration of vancomycin and fluoroquinolones. 
 
b. Select appropriate agents on the basis of the surgical procedure, 
the most common pathogens causing SSIs for a specific procedure, and 
published recommendations. 
(38)
 
 
c. Discontinue agent within 24 hours after surgery. 
29 
 
Although guidelines suggest stopping the antimicrobial agent within 24 hours of 
surgery, there is no evidence that agents given after closure contribute 
to efficacy, and they do contribute to increased resistance 
(41,42)
 and the risk of 
Clostridium difficile disease.
(43)
 
 
d. Adjust dosing on the basis of patient weight; for example: 
i. Use 30 mg/kg for pediatric patients, 2 g of cefazolin for patients 
weighing 80 kg or more, and 3 g for patients weighing 120 kg or more. 
ii. Vancomycin should be dosed at 15 mg/kg.  Gentamicin should be 
dosed at 5 mg/kg for adult patients and 2.5 mg/kg for pediatric patients.  
(a) For morbidly obese patients receiving gentamicin, the 
weight used for dose calculation should be the ideal weight plus 
40% of the excess weight. 
 
e. Redose prophylactic antimicrobial agents for long procedures 
and in cases with excessive blood loss during the procedure. 
i. Prophylactic antimicrobials should be redosed at intervals of 2 half-
lives (measured from time the preoperative dose was administered) in cases that 
exceed this time. 
 
f. Use a combination of parenteral antimicrobial agents and oral 
antimicrobials to reduce the risk of SSI following colorectal 
procedures.
(44-51) 
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i. The additional SSI reduction achieved with mechanical bowel 
preparation has not been studied, but the data supporting use of oral 
antimicrobials have all been generated in combination with mechanical bowel 
preparation. 
ii. Mechanical bowel preparation without oral antimicrobials does not 
decrease the risk of SSI. 
 
2. Do not remove hair at the operative site unless the presence of hair will 
interfere with the operation. Do not use razors 
(53)
 
a. If hair removal is necessary, remove hair outside the operating 
room using clippers or a depilatory agent. 
 
3. Control blood glucose during the immediate postoperative period for cardiac 
surgery patients and noncardiac surgery patients 
(54-57)
 
a. Maintain postoperative blood glucose of 180 mg/dL or lower. 
i. The recommendation of maintaining postoperative blood glucose less 
than 200 mg/dL at 6 AM on postoperative days 1 and 2 is being replaced. In 
2014, this measure will be revised in the SCIP to assess glucose control (180 
mg/dL or lower) in cardiac surgery patients in the time frame of 18-24 hours 
after anesthesia end time. Several societies, experts , and the National Quality 
Forum support this new recommendation.
(58,59)
 
b. Intensive postoperative glucose control (targeting levels less 
than 110 mg/dL) has not been shown to reduce the risk of SSI and may 
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actually lead to higher rates of adverse outcomes, including stroke and 
death.
(60)
 
 
4. Maintain normothermia (temperature of 35.5°C or more) during the 
perioperative period . 
a. Even mild degrees of hypothermia can increase SSI rates. 
Hypothermia may directly impair neutrophil function or impair it 
indirectly by triggering subcutaneous vasoconstriction and subsequent 
tissue hypoxia In addition, hypothermia may increase blood loss, leading 
to wound hematomas or need for transfusion, both of which can increase 
rates of SSI.
(61)
 
b. Randomized controlled trials have shown the benefits of both 
preoperative and intraoperative warming to reduce SSI rates and to 
reduce intraoperative blood loss.
(62-64)
 
 
5. Optimize tissue oxygenation by administering supplemental oxygen during 
and immediately following surgical procedures involving mechanical 
ventilation   
a. Supplemental oxygen is most effective when combined with 
additional strategies to improve tissue oxygenation, including 
maintenance of ormothermia and appropriate volume replacement. The 
available evidence is in patients undergoing surgery with general 
anesthesia using mechanical ventilation. 
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i. Seven randomized clinical trials have been published 
comparing 80% with 30%-35% Fi02 in patients undergoing general anesthesia 
with intraoperative mechanical ventilation and postoperative oxygen delivered 
for 2-6 hours via a nonrebreathing mask. 
ii. Three trials in patients undergoing elective colorectal  
resection and 1 each in open appendectomy and total gastrectomy with 
esophagojejunal anastomosis reported an approximate 40% decrease in the rate 
of SSI. Three of the studies reported protocols that included maintenance of 
perioperative normothermia and liberal fluid replacement. Two trials in mixed 
surgical populations undergoing emergency or elective laparotomy for 
gastrointestinal, gynecologic, or urologic procedures reported different results. 
 
(a.) The large multicenter trial that restricted perioperative 
fluid replacement reported no difference.   
(b.) A follow-up study performed in this population noted 
that patients undergoing cancer surgery who 
received 80% Fi02 had higher rates of mortality 
than patients undergoing cancer surgery who 
received 30% Fi02. 
(c.)  The smaller trial without standardized protocols for 
perioperative normothermia or volume 
replacement reported an increase in SSIs.In this 
study, the 80% Fi02 group had a significantly 
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higher proportion of patients with high body mass 
index (more than 30), higher blood loss, more 
crystalloid infused, and longer operations. This 
group also had 5 patients who remained intubated 
postoperatively (vs 1 in the 35 % group). 
Postoperative intubation was predictive of SSI. 
 
 
b. A meta-analysis of 5 of the above-referenced studies concluded 
that perioperative supplemental oxygen led to a relative risk (RR) 
reduction of 25% for SSI. 
 
6. Use alcohol-containing preoperative skin preparatory agents if no 
contraindication exists. 
a. Alcohol is highly bactericidal and effective for preoperative skin 
antisepsis but does not have persistent activity when used alone. Rapid,  
persistent, and cumulative antisepsis can be achieved by combining 
alcohol with chlorhexidine gluconate or an iodophor. 
i. Alcohol is contraindicated for certain procedures, including procedures 
in which the preparatory agent may pool or not dry (eg, involving hair) 
due to fire risk. Alcohol may also be contraindicated for procedures 
involving mucosa, cornea, or ear. 
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b. The most effective disinfectant to combine with alcohol is 
unclear. 
i. A recent trial of 849 patients undergoing cleancontaminated surgery 
randomized patients to preoperative skin antisepsis with chlorhexidinealcohol 
or povidone-iodine.
(65)
 The overall rate of SSI was significantiy lower in the 
chlorhexidinealcohol group than in the povidone-iodine group (9.5% vs 16% [P 
= .004]; RR, 0.59 [95% confidence interval (CI), 0.41-0.85]). 
ii. In contrast, a single-center study compared povidone- iodine followed 
by isopropyl alcohol versus chlorhexidine-alcohol versus iodine-alcohol using 
a sequential implementation design.
(66)
 General surgical patients who received 
skin antisepsis with iodine-alcohol had the lowest rates of SSI (3.9 per 100 
procedures), compared with 6.4 per 100 procedures for patients who received 
povidone-iodine followed by alcohol and 7.1 per 100 procedures for patients 
who received chlorhexidine-alcohol.In the absence of alcohol, chlorhexidine 
gluconate may have advantages over povidone-iodine, in eluding longer 
residual activity and activity in the presence of blood or serum.
(67)
 
iv. These disinfectants are not interchangeable. Follow the manufacturers' 
instructions to ensure correct application. 
 
7. Use impervious plastic wound protectors for gastrointestinal and biliary tract 
surgery. 
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a. A wound protector is a plastic sheath that lines a wound and can 
facilitate retraction of an incision during surgery without the need for 
additional mechanical retractors. 
 
b. A recent meta-analysis of 6 randomized clinical trials in 1,008 
patients reported that use of a plastic wound protectors was associated 
with a 45% decrease in SSIs. 
i. There was a nonsignificant trend toward greater protective effect using 
a dual-ring protector compared with a single-ring protector. 
 
8. Use a checklist based on the World Health Organization (WHO) checklist to 
ensure compliance with best practices to improve surgical patient safety (quality 
of evidence: 
a. The WHO checklist is a 19-item surgical safety checklist to 
improve adherence with best practices. 
b. A multicenter quasi-experimental study conducted in 8 countries 
demonstrated that use of the WHO checklist led to lower rates of surgical 
complications, including SSI and death. 
 
c. These findings have been confirmed in subsequent single-center 
and multicenter quasi-experimental studies. 
 
9. Perform surveillance for SSI : 
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a. Identify high-risk, high-volume operative procedures to be 
targeted for SSI surveillance on the basis of a risk assessment of patient 
populations, operative procedures performed, and available SSI 
surveillance data. 
 
b. Identify, collect, store, and analyze data needed for the 
surveillance program. 
i. Develop a database for storing, managing, and accessing data collected 
on SSIs. 
ii. Implement a system for collecting data needed to identify SSIs. Data 
are required from surgical and microbiological databases. Obtain the following 
data from surgical databases: patient name, medical record number, date, type 
of procedure, surgeons, anesthesiologists, incision time, wound class, ASA 
score, closure time, and presence of an SSI. Ideally, these data are supplemented 
with process data, including prophylactic agent and dose and time(s) of 
administration of prophylactic agent. For patients diagnosed with an SSI, 
necessary microbiological data include type of SSI, infecting organism and 
antimicrobial susceptibilities, and date of infection. More detailed surgical 
and patient information may be useful for some procedures, including use of 
general anesthesia, emergency or trauma-related surgery, body mass 
index, and diagnosis of diabetes. 
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Prepare periodic SSI reports (time frame will depend on hospital needs and 
volume of targeted procedures). 
iv. Collect denominator data on all patients undergoing targeted 
procedures in order to calculate SSI rates for each type of procedure. 
v. Identify trends (eg, in SSI rates and pathogens causing SSIs). 
  
c. Use updated CDC NHSN definitions for SSI. 
 
d. Perform indirect surveillance for targeted procedures. 
 
e. Perform postoperative surveillance for 30 days; extend the 
postoperative surveillance period to 90 days for certain procedure 
categories. 
i. Procedures that require 90-day surveillance are determined  
by specific procedure codes. 
 
f. Surveillance should be performed on patients readmitted to the 
hospital. 
i. If an SSI is diagnosed at your institution but the surgical procedure was 
performed elsewhere, notify the hospital where the original procedure was 
performed.  
g. Develop a system for routine review and interpretation of SSI rates to 
detect significant increases or outbreaks and to identify areas where additional 
38 
 
resources might be needed to improve SSI rates. If increased rates are identified, 
determine the number of potentially preventable infections that occurred, 
defined as the number of SSIs that occurred during a procedure in which less 
than 100% of recommended practices and processes were completed. 
 
II. Special approaches for preventing SSI 
Standard infection control methods of outbreak investigation are recommended 
for use in locations and/or populations within the hospital with unacceptably 
high SSI rates despite implementation of the basic SSI prevention strategies 
listed above. 
 
1. Screen for S. aureus and decolonize surgical patients with an 
antistaphylococcal agent in the preoperative setting for high-risk procedures, 
including some orthopedic and cardiothoracic procedures. 
 
a. Screening for S. aureus refers to the practice of attempting 
to identify patients colonized with methicillin- susceptible S. aureus (MSSA) 
and/or MRSA. Decolonization refers to the practice of treating patients 
with known S. aureus colonization with antimicrobial and/or antiseptic agents 
to eliminate S. aureus colonization. 
i. There is no standardized approach to either screening or 
decolonizing. Most clinicians attempt to decolonize surgical 
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patients with a combination of chlorhexidine gluconate applied to 
the skin and nasal mupirocin. 
 
b. A Cochrane review concluded that mupirocin alone may be 
effective, particularly in certain groups, including orthopedic and 
cardiothoracic patients. 
Several nonrandomized trials corroborate this conclusion. 
c. Clinical practice guidelines from the American Society of 
Health-System Pharmacists recommend giving mupirocin intranasally to 
all patients with documented S. aureus colonization for orthopedic 
procedures, including total joint replacement and hip fracture repair, and 
cardiac procedures. 
 
d. Some trials demonstrate that preoperative screening for S. 
aureus, coupled with intranasal mupirocin and chlorhexidine bathing is 
effective in reducing SSI for some patients. 
i. For example, a randomized, double-blind, placebocontrolled, 
multicenter trial that evaluated rapid identification of S. aureus nasal carriers 
followed by decolonization was associated with a greater than 2-fold reduction 
in the risk for postoperative infection due to S. aureus and an almost 5-fold 
reduction in risk for deep incisional SSI due to S. aureus. 
(a) This study was performed in a setting with high baseline rates of SSI 
and in the absence of MRSA. 
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e. In contrast, other trials have failed to demonstrate a benefit. 
i. A prospective, interventional cohort study with a crossover design 
involving 21,000 patients concluded that universal, rapid screening for MRSA 
at admission coupled with decolonization of carriers did not reduce the rate of 
SSI due to MRSA. 
ii. A double-blind randomized controlled trial involving more than 4,000 
patients showed that intranasal application of mupirocin, which was not coupled 
with chlorhexidine bathing, did not significantly reduce the S. aureus SSI rate. 
(a) In a secondary analysis of these data, the use of intranasal mupirocin 
was associated with an overall decreased rate of nosocomial S. aureus 
infections among the S. aureus carriers. 
 
f. A recently published meta-analysis of 17 studies concluded that 
decolonization strategies prevent grampositive SSIs, S. aureus SSIs, and 
MRSA SSIs, although there was significant heterogeneity among the 
trials. 
g. Factors that impact the decision to implement screening for S. 
aureus and decolonization include adherence to basic SSI prevention 
strategies, baseline rate of SSI due to S. aureus, individual patient risk 
factors for acquiring SSI due to S. aureus, availability of resources to 
implement the protocol, and ability to follow- up on protocol parameters 
(eg, laboratory results) and adherence. 
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h. Routine preoperative decolonization with mupirocin without 
screening is not currently recommended. 
i. Mupirocin resistance has been documented. 
 
2. Perform antiseptic wound lavage . 
a. Wound lavage is a common practice, although the solution used 
for lavage differs among surgeons.
(68)
 
 
b. Several groups have evaluated whether dilute povidone- iodine 
lavage of the surgical wound can decrease the risk of SSI. A meta-
analysis published in 
2010 evaluated 24 randomized controlled trials and concluded that lavage 
with dilute povidone-iodine decreased the risk of SSI compared with 
nonantiseptic lavage (RR, 0.64 [95% CI, 0.51-0.82]). 
  
3. Perform an SSI risk assessment, 
a. Convene a multidisciplinary team (eg, surgical leadership, 
hospital administration, quality management services, and infection 
control) to identify gaps, improve performance, measure compliance, 
assess impact of interventions, and provide feedback. 
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b. Determine baseline SSI rates by surgical specialty, procedure, 
and/or surgeon to better target your evaluation and interventions. 
 
4. Observe and review operating room personnel and the environment of care in 
the operating room. 
a. Perform direct observation audits of operating room personnel to 
assess operating room processes and practices to identify infection 
control lapses, including but not limited to adherence to process measures 
(antimicrobial prophylaxis choice, timing and duration protocols, hair 
removal, etc), surgical hand antisepsis, patient skin preparation, operative 
technique, surgical attire (wearing and/or laundering outside the operating 
room), and level of operating room traffic. Perform remediation when 
breaches of standards are identified. 
i. Operating room personnel should include surgeons, surgical 
technologists, anesthesiologists, circulating nurses, residents, medical students, 
trainees, and device manufacturer representatives. 
Review instrument processing and flash sterilization logs 
 
ii. Review maintenance records for operating room heating, ventilation, 
and air conditioning system, including results of temperature and relative 
humidity 
testing, and test for maintenance of positive air pressure in the operating 
room(s). 
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5. Observe and review practices in the postanesthesia care unit, surgical 
intensive care unit, and/or surgical ward . 
a. Perform direct observation audits of hand hygiene practices 
among all personnel with direct patient contact. 
b. Evaluate wound care practices. 
c. Perform direct observation audits of environmental cleaning 
practices. 
d. Provide feedback and review infection control measures with 
staff in these postoperative care settings. 
 
III. Approaches that should not be considered a routine part of SSI 
prevention 
1. Do not routinely use vancomycin for antimicrobial prophylaxis 
(quality of evidence: n). 
a. Vancomycin should not routinely be used for antimicrobial 
prophylaxis, but it can be an appropriate agent for specific scenarios. Reserve 
vancomycin for specific clinical circumstances, such as a proven outbreak of 
SSI due to MRSA; high endemic rates of SSI due to MRSA; targeted high-risk 
patients who are at increased risk for SSI due to MRSA (including 
cardiothoracic surgical patients and elderly patients with diabetes); and high-
risk surgical procedures in which an implant is placed. 
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i. No definitions for high endemic rates of SSI due to MRSA have been 
established. 
ii. Studies of the efficacy of vancomycin prophylaxis were published 
prior to the emergence of community- acquired MRSA. 
 
b. Two meta-analyses of studies comparing glycopeptides to beta-
lactam antimicrobial prophylaxis concluded that there was no difference 
in rates of SSI between the 2 antimicrobial prophylaxis regimens. 
 
c. A meta-analysis of 6 studies concluded that prophylaxis with a 
glycopeptide and a second agent was protective against SSI due to gram-
positive organisms compared with prophylaxis with a /3-lactam alone. Of 
note, the 2 randomized controlled trials included in the metaanalysis 
combined a glycopeptide with non-/3-lactam antibiotic(s). Thus, no study 
has prospectively analyzed 
the effect of providing both glycopeptides and (3-lactam antimicrobials for 
preoperative antimicrobial prophylaxis. As vancomycin does not have activity 
against gram-negative pathogens and appears to have less activity 
against MSSA than /3-lactam agents, many experts recommend adding 
vancomycin to standard antimicrobial prophylaxis for the specific clinical 
circumstances described above. 
 
2. Do not routinely delay surgery to provide parenteral nutrition. 
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a. Preoperative administration of total parenteral nutrition has not 
been shown to reduce the risk of SSI in prospective randomized 
controlled trials and may increase the risk of SSI. 
 
b. Individual trials comparing enteral and parenteral perioperative 
nutrition and "immunomodulating" diets containing arginine and/or 
glutamine with "standard" control diets tend to have very small numbers 
and fail to show significant differences. Two recent meta-analyses, 
however, demonstrate reduction in postoperative infectious complication 
in patients receiving enteral diets containing glutamine and/or arginine 
administered either before or after the surgical procedure. 
 
3. Do not routinely use antiseptic-impregnated sutures as a strategy to prevent 
SSIs. 
a. Human volunteer studies involving foreign bodies have 
demonstrated that the presence of surgical sutures decreases the inoculum 
required to cause an SSI from 106 to 102 organisms. 
 
b. Some trials have shown that surgical wound closure with 
triclosan-coated polygactin 910 antimicrobial sutures may decrease the 
risk of SSI compared with standard sutures. For example, a recent 
randomized controlled trial of 410 colorectal surgeries concluded that the 
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rate of SSI decreased more than 50% (9.3% in the control group vs 4.3% 
among cases; P = .05). 
 
c. In contrast, a recent systematic review and meta-analysis 
evaluated 7 randomized clinical trials and concluded that neither rates of 
SSI (odds ratio [OR], 0.77[95% CI, 0.4-1.51]; P = .45) nor rates of 
wound dehiscence (OR, 1.07 [95% CI, 0.21-5.43]; P = .93) were 
statistically different compared with controls.In addition, one small study 
raised concern about higher rates of wound dehiscence while using these 
sutures. 
 
d. The impact of routine use of antiseptic-impregnated sutures on 
development of resistance to antiseptics is unknown. 
 
 
4. Do not routinely use antiseptic drapes as a strategy to prevent SSIs. 
a. An incise drape is an adhesive film that covers the surgical 
incision site to minimize bacterial wound contamination due to 
endogenous flora. These drapes can be impregnated with antiseptic 
chemicals, such as iodophors. 
 
b. A 2007 Cochrane review of 5 trials concluded that nonantiseptic 
incise drapes were associated with a higher risk of SSI compared with no 
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incise drape (RR, 1.23 [95% CI, 1.02-1.48] ), although this association 
may have been caused by one specific study. Two trials (abdominal and 
cardiac surgical patients) compared iodophor-impregnated drapes to no 
drapes. While wound contamination was decreased  in one trial, neither 
trial demonstrated that iodophor-impregnated drapes decreased the rate of 
SSI. A nonrandomized retrospective study similarly concluded that 
impregnated drapes do not prevent SSIs after hernia repair. 
 
IV. Unresolved issues 
 
1. Preoperative bathing with chlorhexidine-containing products. 
a. Preoperative bathing with agents such as chlorhexidine has been shown 
to reduce bacterial colonization of the skin. Several studies have examined the 
utility of preoperative showers, but none has definitively proven that they 
decrease SSI risk.  
i. To gain the maximum antiseptic effect of chlorhexidine, adequate levels of 
CHG must be achieved and maintained on the skin. Typically, adequate 
levels are achieved by allowing CHG to dry completely. New strategies for 
preoperative bathing with chlorhexidine, such as preimpregnated cloths, have 
shown promise, but data are currently insufficient to support this approach. 
 
2. Use of gentamicin-collagen sponges. 
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a. Gentamicin-collagen sponges have been evaluated as a way to decrease SSI 
among colorectal and cardiac surgical patients. 
i. Colorectal surgical patients. Several single-center randomized trials have 
demonstrated that gentamicin- collagen sponges decrease the risk of SSI 
following colorectal procedures.
(69-71)
 The rate of SSI was higher with the 
sponge, however, in a recent large, multicenter randomized clinical trial. 
ii. Cardiothoracic surgical patients. Four randomized controlled trials have 
evaluated the use of gentamicin- collagen sponges in cardiothoracic surgery 
 
Three of these trials demonstrated a decrease in SSIs,
(72-74)
and one 
showed no difference. A recent meta-analysis combining these trials concluded 
that the risk of deep sternal wound infection was significantly lower in patients 
who received a gentamicin- collagen sponge than in patients who did not 
(RR, 0.62 [95% CI, 0.39-0.97]) despite significant heterogeneity among the 
trials.186 
 
USE OF LOCAL ANTIBIOTIC OVER WOUND SITE: 
 Studies have shown the effectiveness of using various antiseptic solutions 
in the skin preparation before making the skin incision, including use of 
alcohol, betadine, chlorhexidine etc.
(65)
  and the use of antiseptic wound lavage 
like dilute povidone iodine lavage 
(68)
 . 
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 The use of Amikacin Sulfate as local antibiotic agent in treating Urinary 
tract infection as been shown in a Japanese study 
(76) 
 , in which amikacin was 
used as bladder wash agent or renal pelvic lavage and vesical instillation. 
There are studies to show the effectiveness of using antibiotic impregnated 
implants or prosthesis to prevent the SSIs. Study by Katsuhiro Tofuku et al. 
(75)
 
showed the effectiveness of using vancomycin impregnated fibrin sealant for 
the prevention of surgical site infection associated with spinal instrumentation. 
 
 Study by Joseph Huh Et Al.
(77)
 showed use of Sustained-release lipid 
particle-encapsulated amikacin applied to contaminated PTFE grafts increased 
survival and decreased postoperative graft infections. Adjunctive use of local, 
delayed-release antibiotics in contaminated vascular beds may allow wider 
clinical use of prosthetic grafts. 
 
 Amikacin also has local action at the wound site with nonspecific actions 
like enhancing growth of granulation tissue 
(78)
. Study by Nandita Pal et.al. 
(79-82)
 
showed that the most common organisms isolated from the surgical site 
infections included Staphylococcus aureus, E.Coli, Klebsiella, Pseudomonas etc 
(82-84)
 and a majority of them showed sensitivity to Inj. Amikacin (used in 
combination to other drugs like Cefaperazone Sulbactum or Piperazillin 
Tazobactum) 
(80-84)
.  
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 Based on these observations , the advantages of using Inj. Amikacin 
which showed less systemic absorption from the local wound site and 
sensitivity to a majority of the organisms isolated from the SSI sites and its once 
daily dosage, we have chosen the use of Inj. Amikacin for this study. 
  
The Inj.,Amikacin , dosage calculated based on weight of the patient and 
applied on the local wound site in the subcutaneous place before the skin 
closure. A Feeding tube (8 or 10 Fr) is placed as a subcutaneous DT and skin 
closed. On POD 1 through POD 3, the same once daily dose of Amikacin is 
injected through the feeding tube and the tube closed.Intentionally no suction 
drainage is applied to the feeding tube, to prevent any additional advantage of 
using suction DT in subcutaneous plane as shown by review of studies done by 
B. Manzoor et al. 
(86)
, that there could be some preventive effect in using 
subcutaneous DT in the development of SSIs.  
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Figure – 3: feeding tube used as Subcutaneous DT 
 
Figure - 4: image of subcutaneous DT used in appendicectomy wound. 
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METHODOLOGY 
 
 
1. Type of study: Prospective and Observational Study 
 
2. Study approval: Prior to commencement of this study - Thesis & 
Ethical Committee of Stanley Medical College and Hospital, 
Chennai had approved the thesis protocol. 
 
3. Place of study: Stanley Medical College and Hospital 
 
4. Period of study: 10 months November 2016 to August 2017 
 
5. Source of data: All cases of abdominal surgeries which falls under 
contaminated (classIII) and dirty (class IV) wounds like emergency 
laprotomies, open appendicectomies etc  
 
6. Sample size: A total of 25 cases and 25 control 
Study group (A): All elective and emergency surgeries of the 
abdomen in which local antibiotic therapy was given 
peroperatively & postoperatively along with systemic antibiotic  
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Control group (B): All cases of contaminated and dirty wounds 
which are matched with the cases ,who received only systemic 
antibiotics 
 
       7.  Selection of patients: 
 
All patients operated for abdominal surgeries, both elective and 
emergency surgeries, which falls under class III (clean 
contaminated)  and class IV ( dirty) 
a) Sampling method- Purposive. 
b) Inclusion criteria- 
All cases of abdominal surgeries which falls under contaminated 
(classIII) and dirty (class IV) wounds like emergency laprotomies, 
open appendicectomies etc  
 
c) Exclusion criteria – 
    Extremes of age <18 yrs >70 yrs 
Patients on immunosuppressants, chemo/radiotherapy, steroids  other 
serious pre-existing cardiovascular, pulmonary and immunological 
disease. 
Uncontrolled diabetic patients 
Clean (Class I) and Clean contaminated (Class II) surgical wounds  
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8. Study procedure: 
 
• Method of sampling was non-random, purposive. 
 
• Ethical clearance will be obtained from the institute ethical 
committee 
 
• Written informed consent will be obtained from all patients before 
subjecting them for the study 
 
• All patients planned for abdominal surgeries were counseled and 
the procedure explained in their local language  
 
• All patients in the group were assigned as study and corresponding 
matched control were selected 
 
• The following parameters will be taken and observations will be 
recorded and tabulated and analyzed to achieve the objective. 
 
• The study group patients which included cases of abdominal 
surgeries with class III and class IV type of wounds, peroperatively a 
single adult dose of Inj.Amikacin was  applied over the ‘subcutaneous 
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cavity’ of the incision site  prior to   skin closure. A Subcutaneous DT 
was kept (8 or 10 size feeding tube). 
 
• Subsequently patient received a single daily adult dose (as per 
body weight) of Inj . Amikacin on the first 3 post operative days 
(POD 1 to POD 3). 
 
• The Subcutaneous DT was intentionally closed without any suction 
drainage, to avoid confounding effecting of keeping a 
subcutaneous suction  DT. 
 
 
 
 
Figure- 5: picture showing the Subcutaneous DT kept in the laprotomy 
wound site 
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9. Parameters to be assessed: 
1) Indication for surgery: 
 
2) Surgical procedure done: 
 
3) Type of Surgical Wound: contaminated/dirty 
 
4) Systemic antibiotic used preoperatively and during immediate post 
operative period 
 
PAST HISTORY     PERSONAL HISTORY  
Previous surgeries      Alcoholic  
Diabetes Mellitus       Smoker  
          Others 
    
GENERAL EXAMINATION  
    Built 
    Nourishment 
    Pallor 
 
Incidence of Surgical site infection: Yes/ No 
If Yes - Grading of Surgical site infection as per ASEPSIS scoring 
 
Wound characteristics 0 <20 20-39 40-59 60-79 >80 
Serous Discharge 0 1 2 3 4 5 
Erythema 0 1 2 3 4 5 
Purulent exudates 0 2 4 6 8 10 
Separation of deep tissues 0 2 4 6 8 10 
 
 Antibiotic change     -10 
 Drainage of pus    -5 
 Wound debridement   -10 
 Isolation of Bacteria   -10 
 Stay as inpatient prolonged >14 days  -5 
 
Highest Total scoring in the first week      - 
Highest Total scoring in the second week - 
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10. Data Analysis: 
 
Statistical methods: 
Diagnosis, total asepsis scoring, antibiotic changes at 1 week, stay as 
Prolonged >14days, Systemic Antibiotic used were considered as outcome 
variables. Case and control group were consider as primary explanatory 
variable. Demographic age and gender were consider as other explanatory 
variable. 
 
Descriptive analysis:  
Descriptive analysis was carried out by mean and standard deviation for 
quantitative variables, frequency and proportion for categorical variables. Data 
was also represented using appropriate diagrams like bar diagram, pie diagram 
and box plots. 
 
Quantitative outcome; 
The association between categorical explanatory variables and 
quantitative outcome was assessed by comparing the mean values. The mean 
differences along with their 95% CI were presented. Independent sample t-
test.Association between quantitative explanatory and outcome variables was 
assessed by calculating person correlation coefficient and the data was 
represented in a scatter diagram. 
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Categorical outcome: 
The association between explanatory variables and categorical outcomes 
was assessed by cross tabulation and comparison of percentages. Chi square test 
was used to test statistical significance. 
 
P value < 0.05 was considered statistically significant. IBM SPSS version 22 
was used for statistical analysis.(1) 
1. Machines IB. IBM SPSS Statistics for Windows, Version 22.0. IBM 
Corp Armonk, NY; 2013. 
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OBSERVATIONS AND RESULTS 
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OBSERVATIONS AND RESULTS 
The study group receives Inj.Amikacin over the wound site before skin 
closure and one 3 consecutive days after surgery. This is in addition to the usual 
Intravenous antibiotic given for all cases of laprotomy surgery. 
The subsequent development of surgical site infection in this study group is 
compared to the control group which does not receive the additional local 
wound site Inj.Amikacin. 
The incidence of surgical site infection and the grading  (based on 
ASEPSIS grading) is done for the both groups for 2 weeks post operatively. 
The second week monitoring is to assess if there is any residual effect of adding 
Amikacin or any adverse effect due to its addition to the treatment regiment. 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
Table 1: Descriptive analysis of group in study population (N=50) 
 
Group Frequency Percentage 
Case 25 50.00% 
Control 25 50.00% 
 
Among the study population, 50% people were in case group and 50% people 
were in control group. (table 1 & figure 1) 
 
 
Figure 6: Bar chart of group distribution in study population (N=50) 
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Table 2: Comparison of mean age between the study groups (N=50) 
Group 
 AGE  
Mean± STD 
Mean 
difference 
95% CI 
P value 
Lower Upper 
Case 39.28 ± 14.32 
-0.88 -8.77 7.01 0.824 
Control 40.16 ± 13.42 
The mean age of case group was 39.28 ± 14.32 and of the control group was 
40.16 ± 13.42. The difference between two groups was statistically not 
significant (p value 0.824). (Table 2) 
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Table 3: Association of group with gender of study population (N=50) 
Gender 
Group 
Chi square P-value 
Case (N=25) Control(N=25) 
Male 21 (84%) 20 (80%) 
0.136 0.713 
Female 4 (16%) 5 (20%) 
 
Among the case group 21 (84%) were male and 4 (16%) were female. The 
number of male and female participants was 20 (80%) and 5 (20%) in control 
group. The differences gender proportion between the two groups was 
statistically not significant (P value 0.713). (Table 3 & figure 2) 
 
Figure 7: Bar chart of comparing gender composition of the two study 
groups (N=50) 
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Table 4: Comparison of mean total asepsis scoring at 1 week between study 
groups (N=50) 
Group 
 Total 
ASEPSIS 
Scoring at 1 
week  
Mean± STD 
Mean 
difference 
95% CI 
P value 
Lower Upper 
Case 16.32 ± 16.67 
-9.52 -18.71 -0.33 0.043 
Control 25.84 ± 15.64 
 
The mean total asepsis scoring at 1 week of case group was 16.32 ± 16.67 and 
the control group was 25.84 ± 15.64. The difference between two groups was 
statistically significant (p value 0.043). (Table 4 & figure 3) 
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Figure 8: Comparison of Total ASEPSIS scoring at 1 week between the two 
groups (N=50) 
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Table 5: Comparison of mean total ASEPSIS scoring at 2 week across the 
two groups (N=50) 
 
Group 
Total 
ASEPSIS 
Scoring at 2 
week  
Mean± STD 
Mean 
difference 
95% CI 
P value 
Lower Upper 
Case 19.76 ± 22.38 
-5.68 -18.15 6.79 0.365 
Control 25.44 ± 21.48 
 
The mean total asepsis scoring at 2 week of case group was 19.76 ± 22.38 and 
the control group was 25.44 ± 21.48. The difference between two groups was 
statistically not significant (p value 0.365). (Table 5 & figure 4) 
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Figure 9: Comparison of Total ASEPSIS scoring at 2 week between the two 
study groups (N=50) 
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Table 6: Association of group with Diagnosis of study population (N= 50) 
 
Diagnosis 
Group 
Case(N=25) Control(N=25) 
Penetrating injury abdomen 2 (8%) 2 (8%) 
Complicated appendicitis- ileostomy 1 (4%) 1 (4%) 
Complicated appendicitis- appendectomy 6 (24%) 6 (24%) 
Duodenal perforation 4 (16%) 4 (16%) 
Gastric perforation 2 (8%) 2 (8%) 
Intestinal obstruction 0 (0%) 1 (4%) 
Intestinal obstruction - ileostomy 2 (8%) 1 (4%) 
Meckel’s diverticulitis – resection anastomosis 2 (8%) 2 (8%) 
Blunt injury abdomen –exploratory laparotomy 3 (12%) 2 (8%) 
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Blunt injury abdomen – resection anastomosis 1 (4%) 1 (4%) 
Sigmoid volvulus – resection colostomy 1 (4%) 1 (4%) 
Small bowel gangrene 1 (4%) 1 (4%) 
Splenic cyst rupture - Splenectomy 0 (0%) 1 (4%) 
 
*No statistical test was applied considering “0” subjects in one of the cells 
Among the case group, 2 (8%) had Penetrating injury abdomen. The proportion 
Complicated appendicitis- ileostomy, Complicated appendicitis- appendectomy 
and Duodenal perforation was   1 (4%), 6 (24%) and 4 (16%) respectively.  The 
number of Penetrating injury abdomen, Complicated appendicitis- ileostomy, 
Complicated appendicitis- appendectomy and Duodenal perforation was2 (8%), 
1 (4%), 6 (24%) and 4 (16%) in control group. (table 6) 
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Table 7: Association of group with antibiotic changes at 1 week of study 
population (N=50) 
 
Antibiotic 
Changes at 1 
Week 
Group 
Chi 
square 
P-value 
Case(N=25) Control(N=25) 
Yes 4 (16%) 13 (52%) 
7.219 0.007 
No 21 (84%) 12 (48%) 
 
In the case group, in 4 (16%) people antibiotic was changed at 1 week. In the 
control group, 13 (52%) people antibiotic was changed at 1 week. The 
differences antibiotic changes at 1 week proportion between the two groups was 
statistically significant (P value 0.007).  (Table 7) 
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Table 8: Association of group with Staying >14days of study population 
(N=50) 
 
 
 
Staying >14 days 
Group 
Chi square P-value 
Case (N=25) Control (N=25) 
Yes 6 (24%) 8 (32%) 
0.397 0.529 
No 19 (76%) 17 (68%) 
 
 
In the case group 6 (24%) patient were in hospital staying>14days. In the 
control group, 8 (32%) patient were in hospital staying >14days. The 
differences hospital staying >14days proportion between the two groups was 
statistically not significant (P value 0.529).  (Table 8) 
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Table 9: Association of group with systemic antibiotic used of study 
population (N=50) 
 
Systemic Antibiotic 
used 
Group 
Chi square P-value 
Case (N=25) Control (N=25) 
Carbapenems 7 (28%) 7 (28%) 
0.114 0.944 Cephalosporins 10 (40%) 11 (44%) 
Piperacillin 
Tazobactum 
8 (32%) 7 (28%) 
 
 
Among the case group was 7 (28%) people were using Carbapenems. The 
proportion Systemic Antibiotic using, Cephalosporins and Piperacillin 
Tazobactum was10 (40%) and 8 (32%)   respectively.  The number of Systemic 
Antibiotic using, Carbapenems, Cephalosporins and Piperacillin Tazobactum 
was 7 (28%), 11 (44%) and 7 (28%) in control group. The differences Systemic 
Antibiotic used proportion with two groups was statically not significant 
(Pvalue 0.944). (Table 9 & figure 4) 
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Figure 10: Bar chart of comparing Systemic Antibiotic used of the two 
study groups (N=50) 
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CONCLUSION 
 
This prospective, interventional and comparative study was 
conducted among 50 purposively selected patients who underwent 
abdominal surgeries categorized as dirty and contaminated wounds in the 
department of General Surgery, Stanley Medical College and Hospital 
from NOV-2016 TO AUG 2017. 
 
  The study was conducted to analyse the effectiveness of 
using local antibiotic over the wound site to prevent surgical site 
infections. The SSIs were graded using on of the standard methods of 
grading ASEPSIS scoring system, which grades the SSIs from 0 to 70 
assessing various parameters. The scoring was done for 1
st
 and 2
nd
 week 
after surgery. 
 
 The cases and controls were sufficiently matched against age, sex, 
age, antibiotics used, the type of surgical diagnosis and treatment given, 
the type of surgical wound. Differences found to be statistically 
insignificant.  
 
 Subsequently the ASEPSIS scores at the end of 1
st
 week of surgery 
showed that the study group patients who received the Inj.Amikacin in 
the local wound site showed significantly lesser grade of SSIs compared 
to that of the control group. The ASEPSIS score at the end of 2
nd
 week of 
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surgery showed lesser grade of SSIs in the study group compared to the 
control though it was statistically insignificant. 
 
 The probability of antibiotic change and duration of stay in the 
patient was lesser in the study group though the later parameter was not 
statistically significant. 
 
Hence overall conclusion is that the patients who received local 
wound site antibiotic (Inj.Amikacin) showed lesser grades of SSIs , more 
so in the 1
st
 week of surgery and lesser need for antibiotic change and 
lesser duration of  stay in hospital during the postoperative period 
compared to the control group which only received the systemic 
antibiotics. 
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LIMITATIONS OF THE STUDY 
Number of Limitations decrease the significance of this study 
1) Very short duration of study 
2) Lesser number of cases (due to unavailability during the study period) 
3) Other associated parameters like the general condition of the patient and 
comorbidies were not thoroughly matched 
4) The use of Subcutaneous DT (in spite of not being functional ) may have 
some positive or negative effect on the outcome  
 
RECOMMENDATIONS 
Based on this prospective study, it can be proposed that use of  Local 
application of Inj. Amikacin is a cost effective and effective method with less 
adverse effects in preventing surgical site infection in the immediate post 
operative period 
 It is also recommended to combine the use of a subcutaneous suction DT 
along with the once daily dose of Amikacin, for enhancing the preventive 
ability. 
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1. KALLESHW
ARAN 
42/M 1712164 case GANGRENO
US 
APPENDICITI
S 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 - 4 - - - 10 - 24 
0 0 - 4 - - - - - 4 
2. SUGANTHI 41/F 1714841 Contro
l 
PERFORATE
D APPENDIX 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 4 4 10 5 - 10 - 43 
5 5 8 6 10 5 - 10 5 54 
3. ARUMUGAM  43/M 1714310 case PERFORATE
D 
APPENDICITI
S 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 10 8 10 5 - 10 -- 53 
5 5 10 10 10 5 - 10 5 60 
4.. RENUKA 49/F 1714910 Contro
l 
GANGRENO
US 
APPENDICITI
S 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 10 4 10 5 - 10 - 49 
5 5 10 4 - - - - - 24 
5. VASANTHA 
KUMAR 
17/M 1742271 CASE PERFORATE
D 
APPENDICITI
S 
CEPHALO
SPORINS 
- 2 - - - - - - - 2 
- - - - - - - - - 0 
6. VIJAYALAK
SHMI 
21/M 1712276 CONT
ROL 
GANGRENO
US 
APPENDICITI
S 
CEPHALO
SPORINS 
2 4 - - 10 - - 10 - 26 
- - - - - - - - - 0 
7. RATHNAM 55/M 1733873 case APPENDICITI
S 
GANGRENO
US 
ILEOTOSMY 
CARBAPE
NEMS 
5 5 - - - - - - - 10 
5 5 5 2 10 - - 10 - 37 
8. SHERMILA 35/F 1734425 Contro
l 
APPENDICU
LAR 
PERFORATIO
N 
ILEOSTOMY 
CARBAPE
NEMS 
5 5 5 2 - - - 10 - 27 
5 5 5 8 10 - - 10 5 48 
9. ROOPAVATH
Y 
20/F 1713264 CASE GANGRENO
US 
APPENDICITI
S 
CEPHALO
SPORINS 
3 3 - - - - - - - 6 
3 2 - - - - - - - 5 
10
. 
SARANYA 17/F 1714069 CASE APPENDICU
LAR 
CEPHALO
SPORINS 
4 3 - - - - - - - 7 
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ABSCESS 
2 - - - - - - - - 2 
11
. 
MD USMAN 
ALI 
19/M 1713548 Contro
l 
PERFORATE
D 
APPENDICITI
S 
CEPHALO
SPORINS 
- 2 - - - - - - - 2 
3 4 6 - - - - - - 13 
12
. 
EMMANUAL  20/M 1720012 CONT
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PERFORATE
D 
APPENDICITI
S 
CEPHALO
SPORINS 
- 2 - - - - - 10 - 12 
3 4 8 10 - - - - - 25 
13
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US 
APPENDICITI
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CEPHALO
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AN 
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US 
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CEPHALO
SPORINS 
3 3 8 - - - - - - 14 
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15. VINOTH 
KUMAR 
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RESECTION 
ANASTOMO
SIS 
CEPHALO
SPORINS 
5 5 - 4 - - - 10 - 24 
0 0 - 4 - - - - - 4 
16. MUTHU 30/M 1717280 Contro
l 
RTA 
EXPLORATO
RY 
LAPROTOM
Y 
CEPHALO
SPORINS 
5 5 4 4 10 5 - 10 - 43 
5 5 8 6 10 5 - 10 5 54 
17. ANNAPOOR
ANI 
52/F  1720483 case RTA 
EXPLORATO
RY 
LAPROTOM
Y 
CEPHALO
SPORINS 
5 5 10 8 10 5 - 10 -- 53 
5 5 10 10 10 5 - 10 5 60 
18. VASUDHERA
N 
38/M 1733713 CONT
ROL 
RTA 
HEMOPERIT
ONEUM 
CEPHALO
SPORINS 
5 5 10 4 10 5 - - - 39 
5 5 10 4 - - - - - 24 
19. AMIRTHA 60/F 1737502 CASE RTA 
EXPLORATO
RY 
LAPROTOM
Y 
CARBAPE
NEMS 
- 2 - - - - - - - 2 
- - - - - - - - - 0 
20. BALARAMA
N 
60/M 1730509 Contro
l 
RTA 
LAPROTOM
Y 
RESECTION 
ANASTOMO
SIS 
CARBAPE
NEMS 
2 4 - - 10 - - 10 - 26 
- - - - - - - - - 0 
21. IRUTHAYAR
AJ 
34/M 1734077 Contro
l 
STAB 
INJURY 
RESECTION 
ANASTOMO
SIS 
CEPHALO
SPORINS 
5 5 - - - - - - - 10 
5 5 5 2 10 - - 10 - 37 
22. JAYARAJ 24/M 1733873 Case STAB 
INJURY 
SPLENECTO
MY 
CEPHALO
SPORINS 
5 5 5 2 - - - - - 17 
5 5 5 8 10 - - 10 5 48 
23. ANBU 56/M 1724123 Contro SPLENIC CEPHALO 3 3 - - - - - - - 6 
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l CYST 
RUPTURE 
SPORINS 
3 2 - - - - - - - 5 
24. CHANDRASE
KAR 
43/M 1738910 Case RTA 
EXPLORATO
RY 
LAPROTOM
Y 
CEPHALO
SPORINS 
4 3 - - - - - - - 7 
2 - - - - - - - - 2 
25. MOHAN RAJ 57/M 1734205 Case ACCIDENTA
L FALL 
BLUNT 
INJURY 
ILEOSTOMY 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 - 4 - - - 10 - 24 
0 0 - 4 - - - - - 4 
26. KALTAN 50/M 1711834 Contro
l 
PENETRATIN
G INJURY - 
LAPROTOM
Y 
PIPERAZI
LLIN 
TAZOBAC
TUM 
5 5 4 4 10 5 - 10 - 43 
5 5 8 6 10 5 - 10 5 54 
27. MANI  26/M 1734891 CASE DU 
PERFORATIO
N 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 10 8 10 5 - 10 -- 53 
5 5 10 10 10 5 - 10 5 60 
28. RAJAIAH 40/M 1712355 CONT
ROL 
DU 
PERFORATIO
N 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 10 4 10 5 - 10 - 49 
5 5 10 4 - - - - - 24 
29. DHARMAN 24/M 1729444 CASE DU 
PERFORATIO
N 
CARBAPE
NEMS 
- 2 - - - - - - - 2 
- - - - - - - - - 0 
30. MANI 34/M 1729374 CONT
ROL 
DU 
PERFORATIO
N 
CARBAPE
NEMS 
2 4 - - 10 - - 10 - 26 
- - - - - - - - - 0 
31. CHINNAIYA
N 
50/M 1736713 CASE DU 
PERFORATIO
N 
CEPHALO
SPORINS 
5 5 - - - - - - - 10 
5 5 5 2 10 - - 10 - 37 
32. KUMARAM
MAL 
50/F 1725833 CONT
ROL 
DU 
PERFORATIO
N 
CEPHALO
SPORINS 
5 5 5 2 - - - 10 - 27 
5 5 5 8 10 - - 10 5 48 
33. VIJAY 22/M 1736771 CONT
ROL 
DU 
PEERFORATI
ON 
PIPRAZIL
LIN 
TAZOBAC
TUM 
3 3 - - - - - - - 6 
3 2 - - - - - - - 5 
34. KARUPAIYA 41/M 1747662 CASE DU 
PERFORATIO
N 
PIPRAZIL
LIN 
TAZOBAC
TUM 
4 3 - - - - - - - 7 
2 - - - - - - - - 2 
35. RAVI  58/M 1738762 CASE GASTRIC 
PERFORATIO
N 
CARBAPE
NEMS 
- 2 - - - - - - - 2 
3 4 6 - - - - - - 13 
36. RAMAN 63/M 1748053 CONT
ROL 
GASTRIC 
PERFORATIO
N 
CARBAPE
NEMS 
- 2 - - - - - 10 - 12 
3 4 8 10 - - - - - 25 
37. MANIKAND
AN 
43/M 1720112 CASE GASTRIC 
PERFORATIO
N 
CARBAPE
NEMS 
2 3 6 - - - - - - 11 
5 5 8 10 - - - 10 5 43 
38. MANI 45/M 1726621 CONT
ROL 
GASTRIC 
PERFORATIO
N 
CARBAPE
NEMS 
3 3 8 - - - - - - 14 
4 - 2 - - - - 10 - 16 
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39. JANAKIRAM
AN 
40/M 1722682 CASE INTESTINAL 
OBSTRUCTI
ON 
RESECTION 
ILEOSTOMY 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 - 4 - - - 10 - 24 
0 0 - 4 - - - - - 4 
40. JANCY RANI 31/F 1730725 CONT
ROL 
INTESTINAL 
OBSTRUCTI
ON 
ADHESIOLY
SIS 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 4 4 10 5 - 10 - 43 
5 5 8 6 10 5 - 10 5 54 
41. MUTHUPAN
DI 
32/M 1733358 CONT
ROL 
INTESTINAL 
OBSTRUCTI
ON 
ILEOSTMY 
CEPHALO
SPORINS 
5 5 10 8 10 5 - 10 -- 53 
5 5 10 10 10 5 - 10 5 60 
42. JAYARAJ 62/M 1740360 CASE INTESTINAL 
OBSTRUCTI
ON 
RESECTION 
ANASTOMS
OSIS 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 10 4 10 5 - - - 39 
5 5 10 4 - - - - - 24 
43. MAHIMAIRA
J 
39/M 1738762 CASE SMV 
THROMBOSI
S BOWEL 
GANGRENE 
CARBAPE
NEMS 
- 2 - - - - - - - 2 
- - - - - - - - - 0 
44. MANIKAND
AN 
42/M 1713964 CONT
ROL 
SMALL 
BOWEL 
GANGRENE 
CARBAPE
NEMS 
2 4 - - 10 - - 10 - 26 
- - - - - - - - - 0 
45. KARTHICK 25/M 1718881 CASE MECKELS 
DIVERTICUL
ITIS 
RESECTION 
ANASTOMO
SIS 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 - - - - - - - 10 
5 5 5 2 10 - - 10 - 37 
46. KANNAN 46/M 1722163 CONT
ROL 
MECKELS 
DIVERTICUL
ITIS 
RESECTION 
ANASTOMO
SIS 
PIPRAZIL
LIN 
TAZOBAC
TUM 
5 5 5 2 - - - - - 17 
5 5 5 8 10 - - 10 5 48 
47. THULASIDH
ARAN 
43/M 1736039 CASE SIGMOID 
VOLVULUS 
RESECTION 
OSTOMY 
CARBAPE
NEMS 
3 3 - - - - - - - 6 
3 2 - - - - - - - 5 
48. SOMASEKAR 70/M 1779326 CONT
ROL 
SIGMOID 
VOLVULUS 
RESECTION 
OSTOMY 
CARBAPE
NEMS 
4 3 - - - - - - - 7 
2 - - - - - - - - 2 
49. SANTHOSH  28/M 1712072 CASE MECKELS 
DIVERTICUL
ITIS 
RESECTION 
ANASTOMO
SIS 
CEPHALO
SPORINS 
- 2 - - - - - - - 2 
- - - - - - - - - 0 
50. GANESH 36/M 1712114 CONT
ROL 
MECKEL 
DIVERTICUL
ITIS 
RESECTION 
ANASTOMO
SIS 
cephalospor
ins 
2 4 - - 10 - - 10 - 26 
- - - - - - - - - 0 
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Name :                                                   Age :               Sex :                            IP NO:  
 
Indication for surgery: 
 
 
 
Surgical procedure done: 
 
 
 
Type of Surgical Wound: contaminated/dirty 
 
 
 
Group –  
 study group (local amikacin with    
systemic antibiotic)  
Systemic antibiotic used: 
- Carbapenem 
- Piperacillin tazobactum 
- Cephalosporins 
 
 control group (only systemic antibiotic) 
 
PAST HISTORY      PERSONAL HISTORY  
Previous surgeries     Alcoholic  
Diabetes Mellitus      Smoker  
          Others 
    
GENERAL EXAMINATION  
    Built 
    Nourishment 
    Pallor 
 
Incidence of Surgical site infection: Yes/ No 
If Yes - Grading of Surgical site infection as per ASEPSIS scoring 
 
Wound characteristics 0 <20 20-39 40-59 60-79 >80 
Serous Discharge 0 1 2 3 4 5 
Erythema 0 1 2 3 4 5 
Purulent exudates 0 2 4 6 8 10 
Separation of deep tissues 0 2 4 6 8 10 
 
 Antibiotic change    -10 
 Drainage of pus    -5 
 Wound debridement   -10 
 Isolation of Bacteria   -10 
 Stay as inpatient prolonged >14 days  -5 
 
Highest Total scoring in the first week      - 
Highest Total scoring in the second week - 
 
 
Investigations 
Hb: 
TC: 
DC: 
 
UREA: 
CREATININE: 
BLOOD SUGAR 
SR.ELECTROLYTES  
 
LFT 
  Proteins  
  Albumin 
 
 
Pre-op Post-op 
